[company_age]4.0[/company_age][employees]1-10 employees[/employees][funding]seed[/funding][description]Tagomics is a biotechnology company that develops and commercializes multiomic-based technologies for clinical applications. The company's proprietary platform, TagSeq, enables the simultaneous analysis of DNA, RNA, and protein from a single sample, providing a comprehensive view of the molecular landscape of a disease. Tagomics' lead product, TagSeqDx, is a diagnostic test for the early detection of cancer. The company is also developing other products for the diagnosis and monitoring of a variety of diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Tagomics' multiomic platform offers several advantages over traditional diagnostic methods, including its ability to provide a more comprehensive view of the disease, its high sensitivity and specificity, and its ability to be used with a variety of sample types. The company's technology is based on a novel chemoenzymatic method that sorts hypomethylated and hypermethylated biomolecules, providing access to epigenetic biomarkers associated with diseases. This approach allows for the identification of disease-specific biomarkers that can be used for early detection, diagnosis, and monitoring. Tagomics is headquartered in Cambridge, United Kingdom, and has a subsidiary in the United States. The company is a spin-off from the University of Cambridge and is backed by a number of venture capital firms.[/description][ps]Multiomic-based technologies for clinical applications, including the TagSeq platform and the TagSeqDx diagnostic test.[/ps]